Concise Review: Induced Pluripotent Stem Cell-Derived Mesenchymal Stem Cells: Progress Toward Safe Clinical Products

被引:194
作者
Jung, Yunjoon [1 ,2 ,3 ]
Bauer, Gerhard [1 ,2 ,4 ]
Nolta, Jan A. [1 ,2 ,3 ,4 ]
机构
[1] Univ Calif Davis, Stem Cell Program, Sacramento, CA 95817 USA
[2] Univ Calif Davis, Inst Regenerat Cures, Sacramento, CA 95817 USA
[3] Univ Calif Davis, Dept Biomed Engn, Sacramento, CA 95817 USA
[4] Univ Calif Davis, Dept Internal Med, Div Hematol Oncol, Sacramento, CA 95817 USA
基金
美国国家卫生研究院;
关键词
Mesenchymal stem cells; Induced pluripotent stem cells; Cellular therapy; Clinical trials; Regenerative medicine; MARROW STROMAL CELLS; VERSUS-HOST-DISEASE; GENE-THERAPY; BONE-MARROW; COPY NUMBER; MOUSE MODEL; TRANSPLANTATION; PROLIFERATION; GENERATION; EXPRESS;
D O I
10.1002/stem.727
中图分类号
Q813 [细胞工程];
学科分类号
摘要
Adult stem cell therapies have provided success for more than 50 years, through reconstitution of the hematopoietic system using bone marrow, umbilical cord blood, and mobilized peripheral blood transplantation. Mesenchymal stem cell (MSC)-mediated therapy is a fast-growing field that has proven safe and effective in the treatment of various degenerative diseases and tissue injuries. Since the first derivation of embryonic stem cells (ESCs) and induced pluripotent stem cells (iPSCs), there has been impressive progress toward developing safe clinical applications from PSCs. Recent successes in transgene-free iPSC reprogramming have brought attention to the potential of clinical applications of these pluripotent cells, but key hurdles must be overcome, which are discussed in this review. Looking to the future, it could be advantageous to derive MSC from iPSC or human ESC in cases where genetic engineering is needed, since in the PSCs, clones with safe harbor vector integration could be selected, expanded, and differentiated. Here, we describe the status of the progress of the use of MSC and PSCs in clinical trials and analyze the challenges that should be overcome before iPSC-derived MSC therapy can be used widely in the clinic. STEM CELLS 2012;30:4247
引用
收藏
页码:42 / 47
页数:6
相关论文
共 61 条
[1]   Human mesenchymal stem cells modulate allogeneic immune cell responses [J].
Aggarwal, S ;
Pittenger, MF .
BLOOD, 2005, 105 (04) :1815-1822
[2]   Gene Therapy for Immunodeficiency Due to Adenosine Deaminase Deficiency. [J].
Aiuti, Alessandro ;
Cattaneo, Federica ;
Galimberti, Stefania ;
Benninghoff, Ulrike ;
Cassani, Barbara ;
Callegaro, Luciano ;
Scaramuzza, Samantha ;
Andolfi, Grazia ;
Mirolo, Massimiliano ;
Brigida, Immacolata ;
Tabucchi, Antonella ;
Carlucci, Filippo ;
Eibl, Martha ;
Aker, Memet ;
Slavin, Shimon ;
Al-Mousa, Hamoud ;
Al Ghonaium, Abdulaziz ;
Ferster, Alina ;
Duppenthaler, Andrea ;
Notarangelo, Luigi ;
Wintergerst, Uwe ;
Buckley, Rebecca H. ;
Bregni, Marco ;
Marktel, Sarah ;
Valsecchi, Maria Grazia ;
Rossi, Paolo ;
Ciceri, Fabio ;
Miniero, Roberto ;
Bordignon, Claudio ;
Roncarolo, Maria-Grazia .
NEW ENGLAND JOURNAL OF MEDICINE, 2009, 360 (05) :447-458
[3]   Donor-Derived Brain Tumor Following Neural Stem Cell Transplantation in an Ataxia Telangiectasia Patient [J].
Amariglio, Ninette ;
Hirshberg, Abraham ;
Scheithauer, Bernd W. ;
Cohen, Yoram ;
Loewenthal, Ron ;
Trakhtenbrot, Luba ;
Paz, Nurit ;
Koren-Michowitz, Maya ;
Waldman, Dalia ;
Leider-Trejo, Leonor ;
Toren, Amos ;
Constantini, Shlomi ;
Rechavi, Gideon .
PLOS MEDICINE, 2009, 6 (02) :221-231
[4]   Mesenchymal stem cell therapy: Two steps forward, one step back [J].
Ankrum, James ;
Karp, Jeffrey M. .
TRENDS IN MOLECULAR MEDICINE, 2010, 16 (05) :203-209
[5]   In vivo biosafety model to assess the risk of adverse events from retroviral and lentiviral vectors [J].
Bauer, Gerhard ;
Dao, Mo A. ;
Case, Scott S. ;
Meyerrose, Todd ;
Wirthlin, Louisa ;
Zhou, Ping ;
Wang, Xiuli ;
Herrbrich, Phillip ;
Arevalo, Jesusa ;
Csik, Susie ;
Skelton, Dianne C. ;
Walker, Jon ;
Pepper, Karen ;
Kohn, Donald B. ;
Nolta, Jan A. .
MOLECULAR THERAPY, 2008, 16 (07) :1308-1315
[6]   Stem-Cell Gene Therapy for the Wiskott-Aldrich Syndrome [J].
Boztug, Kaan ;
Schmidt, Manfred ;
Schwarzer, Adrian ;
Banerjee, Pinaki P. ;
Diez, Ines Avedillo ;
Dewey, Ricardo A. ;
Boehm, Marie ;
Nowrouzi, Ali ;
Ball, Claudia R. ;
Glimm, Hanno ;
Naundorf, Sonja ;
Kuehlcke, Klaus ;
Blasczyk, Rainer ;
Kondratenko, Irina ;
Marodi, Laszlo ;
Orange, Jordan S. ;
von Kalle, Christof ;
Klein, Christoph .
NEW ENGLAND JOURNAL OF MEDICINE, 2010, 363 (20) :1918-1927
[7]   Transplantation of gene-modified human bone marrow stromal cells into mouse-human bone chimeras [J].
Brouard, N ;
Chapel, A ;
Thierry, D ;
Charbord, P ;
Péault, B .
JOURNAL OF HEMATOTHERAPY & STEM CELL RESEARCH, 2000, 9 (02) :175-181
[8]   Revascularization of ischemic limbs after transplantation of human bone marrow cells with high aldehyde dehydrogenase activity [J].
Capoccia, Benjamin J. ;
Robson, Debra L. ;
Levac, Krysta D. ;
Maxwell, Dustin J. ;
Hohm, Sarah A. ;
Neelamkavil, Marian J. ;
Bell, Gillian I. ;
Xenocostas, Anargyros ;
Link, Daniel C. ;
Piwnica-Worms, David ;
Nolta, Jan A. ;
Hess, David A. .
BLOOD, 2009, 113 (21) :5340-5351
[9]   Transfusion independence and HMGA2 activation after gene therapy of human β-thalassaemia [J].
Cavazzana-Calvo, Marina ;
Payen, Emmanuel ;
Negre, Olivier ;
Wang, Gary ;
Hehir, Kathleen ;
Fusil, Floriane ;
Down, Julian ;
Denaro, Maria ;
Brady, Troy ;
Westerman, Karen ;
Cavallesco, Resy ;
Gillet-Legrand, Beatrix ;
Caccavelli, Laure ;
Sgarra, Riccardo ;
Maouche-Chretien, Leila ;
Bernaudin, Francoise ;
Girot, Robert ;
Dorazio, Ronald ;
Mulder, Geert-Jan ;
Polack, Axel ;
Bank, Arthur ;
Soulier, Jean ;
Larghero, Jerome ;
Kabbara, Nabil ;
Dalle, Bruno ;
Gourmel, Bernard ;
Socie, Gerard ;
Chretien, Stany ;
Cartier, Nathalie ;
Aubourg, Patrick ;
Fischer, Alain ;
Cornetta, Kenneth ;
Galacteros, Frederic ;
Beuzard, Yves ;
Gluckman, Eliane ;
Bushman, Frederick ;
Hacein-Bey-Abina, Salima ;
Leboulch, Philippe .
NATURE, 2010, 467 (7313) :318-U94
[10]   Turning straw into gold: directing cell fate for regenerative medicine [J].
Cohen, Dena E. ;
Melton, Douglas .
NATURE REVIEWS GENETICS, 2011, 12 (04) :243-252